Clinical guidelines recommend using Bisphosphonates for CRPS, but evidence supporting this treatment has been limited. A recent systematic review and meta-analysis sought to clarify the benefits and harms of this approach. Researchers compared bisphosphonate treatment against a placebo in adults diagnosed with Complex Regional Pain Syndrome (CRPS) type I or II. This analysis, which included 11 trials and 754 participants, offers important insights for clinicians.
Efficacy of Bisphosphonates for CRPS
The meta-analysis evaluated five specific bisphosphonates: alendronate, clodronate, neridronate, pamidronate, and zoledronate. Interestingly, the study population primarily included patients with CRPS type I (97%).
In the immediate term (up to four weeks), bisphosphonates likely cause little to no difference in pain intensity. Conversely, bisphosphonates may reduce pain intensity in the short term, defined as four weeks to three months. This reduction represents the primary time point where efficacy appears. Nevertheless, the certainty of this evidence remains low.
Moving forward, bisphosphonates may result in little to no difference in pain intensity over the medium term (three to six months). Furthermore, the long-term effects (beyond six months) of these medications on pain intensity are very uncertain. Therefore, clinicians must manage patient expectations regarding sustained pain relief.
Adverse Events and Safety Profile
The study found that bisphosphonates probably increase the risk for adverse events. The risk ratio suggested a clear, though small, increase in overall adverse events. This evidence carries a moderate certainty. Therefore, doctors must counsel patients carefully on potential side effects before initiating therapy. Adverse events often include flu-like symptoms, such as fever and diffuse musculoskeletal pain, especially following intravenous administration.
Limitations and Future Research Needs
This systematic review highlights several key limitations in the current body of evidence. First, the data shows high heterogeneity across the included studies. Second, researchers report uncertain effects in the medium- and long-term follow-up periods. Moreover, the evidence mostly applies to CRPS type I patients. Finally, the trials included non-U.S.-approved formulations like neridronate and clodronate, which limits generalizability for some regions.
In conclusion, bisphosphonates may reduce CRPS pain intensity but only in the short term. However, the treatment introduces an increased risk of adverse events. Consequently, future research must focus on identifying which CRPS patients are most likely to benefit from bisphosphonates, thus resolving the current therapeutic uncertainty.
Frequently Asked Questions
Q1: Do bisphosphonates provide long-term pain relief for CRPS?
A: The evidence is very uncertain regarding the long-term effects (six months and beyond) of bisphosphonates on CRPS pain intensity. The most notable pain reduction appears to occur only in the short term (4 weeks to 3 months).
Q2: What are the main adverse events associated with bisphosphonate treatment for CRPS?
A: Bisphosphonates probably increase the risk of general adverse events, with moderate certainty in the evidence. These events commonly include acute phase reactions, such as fever and flu-like symptoms.
Q3: Which specific bisphosphonates were included in this meta-analysis?
A: The review included trials evaluating alendronate, clodronate, neridronate, pamidronate, and zoledronate. However, it is important to note that formulations like neridronate and clodronate are not approved in all countries.
References
- Ferraro MC et al. Efficacy and Safety of Bisphosphonates for Complex Regional Pain Syndrome : A Systematic Review and Meta-analysis. Ann Intern Med. 2025 Dec 16. doi: 10.7326/ANNALS-25-03693. PMID: 41397259.
- Bone meds may help chronic pain. Pharmacy Daily. 2025 Dec 16.
- Long-term effectiveness and predictors of bisphosphonate treatment in type I complex regional pain syndrome. Clinical and Experimental Rheumatology. 2024; 42: 961-966.
- Bisphosphonates for treatment of Complex Regional Pain Syndrome type 1: A systematic literature review and meta-analysis of randomized controlled trials versus placebo. ResearchGate.